Kunte Sophie Carina, Kazmierczak Philipp M, Holzgreve Adrien, Stief Christian G, Casuscelli Jozefina, Unterrainer Marcus, Unterrainer Lena M
Klinik und Poliklinik für Nuklearmedizin, LMU-Klinikum, LMU München, Marchioninistr. 15, 81377, München, Deutschland.
Bayerisches Zentrum für Krebsforschung (BZKF), partner site München, München, Deutschland.
Urologie. 2025 Aug 18. doi: 10.1007/s00120-025-02659-6.
Over the last few years diagnostic and therapeutic advances have contributed to the significant relevance of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and PSMA radioligand therapy in patients with advanced prostate cancer (PCa). The PSMA-PET/CT has a higher accuracy for the detection of PCa metastases than the combination of CT and bone scintigraphy. Based on the theranostic approach, PSMA radioligand therapy can be performed in the castration-resistant stage in patients with sufficient PSMA expression of the tumor lesions in PSMA PET/CT and progression of PCa after chemotherapy and therapy with abiraterone or an androgen receptor signalling pathway inhibitor. Over the next few years, a large number of studies on the effectiveness of PSMA radioligand therapy in earlier stages of PCa and as part of combination therapies with other drugs will be conducted.
在过去几年中，诊断和治疗方面的进展使得前列腺特异性膜抗原（PSMA）正电子发射断层扫描/计算机断层扫描（PET/CT）以及PSMA放射性配体疗法在晚期前列腺癌（PCa）患者中具有重要意义。与CT和骨闪烁显像联合使用相比，PSMA-PET/CT在检测PCa转移方面具有更高的准确性。基于治疗诊断方法，对于PSMA PET/CT显示肿瘤病灶有足够PSMA表达且在化疗以及使用阿比特龙或雄激素受体信号通路抑制剂治疗后PCa仍进展的去势抵抗阶段患者，可进行PSMA放射性配体治疗。在未来几年，将开展大量关于PSMA放射性配体疗法在PCa早期阶段的有效性以及作为与其他药物联合治疗一部分的研究。
